New strategy aims to eliminate residual bladder cancer after drug combo

NCT ID NCT07579195

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 5 times

Summary

This early-phase trial tests whether adding radiation therapy or bladder removal surgery can safely eliminate remaining cancer in patients with advanced bladder cancer who have already responded to a drug combination. The study enrolls 12 adults with muscle-invasive bladder cancer that has spread to lymph nodes or a few distant sites. The goal is to see if this approach can delay cancer progression and allow patients to stop systemic therapy sooner, reducing long-term side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: enfortumab vedotin plus pembrolizumab followed by radiation therapy or surgery
What this could lead to: If successful, this approach could allow patients to stop systemic therapy earlier, reducing side effects while maintaining cancer control.
What could go wrong: This is a small, early-phase feasibility trial with only 12 participants, so results may not apply broadly. Radiation and surgery carry risks of side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSCLE INVASIVE BLADDER CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma stage IVb bladder cancer Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUSCLE INVASIVE BLADDER CARCINOMA STAGE III BLADDER CANCER AJCC V8 STAGE IV BLADDER CANCER AJCC V8

Contacts and locations

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.